|
Code
|
|
Definition
|
|
|
U
|
|
PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
|
|
|
U-1
|
|
PREVENTION OF PREGNANCY
|
|
|
U-2
|
|
TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
|
|
|
U-3
|
|
TREATMENT OF HYPERTENSION
|
|
|
U-4
|
|
PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
|
|
|
U-5
|
|
METHOD OF PRODUCING BRONCHODILATION
|
|
|
U-6
|
|
METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
|
|
|
U-7
|
|
INCREASING CARDIAC CONTRACTILITY
|
|
|
U-8
|
|
ACUTE MYOCARDIAL INFARCTION
|
|
|
U-9
|
|
CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT
|
|
|
U-10
|
|
DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALMIC MALFUNCTIONS OR LESIONS IN HUMANS
|
|
|
U-11
|
|
TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
|
|
|
U-12
|
|
METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
|
|
|
U-13
|
|
A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
|
|
|
U-14
|
|
ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
|
|
|
U-15
|
|
METHOD OF LOWERING INTRAOCULAR PRESSURE
|
|
|
U-16
|
|
USE IN LUNG SCANNING PROCEDURES
|
|
|
U-17
|
|
TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
|
|
|
U-18
|
|
METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
|
|
|
U-19
|
|
TREATMENT OF INFLAMMATION
|
|
|
U-20
|
|
A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
|
|
|
U-21
|
|
TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
|
|
|
U-22
|
|
METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
|
|
|
U-23
|
|
METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
|
|
|
U-24
|
|
METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
|
|
|
U-25
|
|
REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
|
|
|
U-26
|
|
REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
|
|
|
U-27
|
|
DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
|
|
|
U-28
|
|
CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
|
|
|
U-29
|
|
CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
|
|
|
U-30
|
|
CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
|
|
|
U-31
|
|
INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
|
|
|
U-32
|
|
PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
|
|
|
U-33
|
|
TREATING VIRAL INFECTIONS IN A MAMMAL
|
|
|
U-34
|
|
TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
|
|
|
U-35
|
|
TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
|
|
|
U-36
|
|
METHODS OF TREATING BACTERIAL ILLNESSES
|
|
|
U-37
|
|
METHOD OF TREATING GASTROINTESTINAL DISEASE
|
|
|
U-38
|
|
TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
|
|
|
U-39
|
|
ANGINA PECTORIS
|
|
|
U-40
|
|
METHOD OF TREATMENT OF BURNS
|
|
|
U-41
|
|
METHOD OF TREATING CARDIAC ARRHYTHMIAS
|
|
|
U-42
|
|
ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
|
|
|
U-43
|
|
MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
|
|
|
U-44
|
|
RELIEF OF NAUSEA AND VOMITING
|
|
|
U-45
|
|
TREATMENT OF INFLAMMATION AND ANALGESIA
|
|
|
U-46
|
|
TREATMENT OF PANIC DISORDER
|
|
|
U-47
|
|
STIMULATION OF THE RELEASE OF GROWTH HORMONE
|
|
|
U-48
|
|
ANALGESIA
|
|
|
U-49
|
|
SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA
|
|
|
U-50
|
|
USE IN TREATING INFLAMMATORY DERMATOSES
|
|
|
U-51
|
|
BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
|
|
|
U-52
|
|
TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
|
|
|
U-53
|
|
HYPERCALCEMIA OF MALIGNANCY
|
|
|
U-54
|
|
REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
|
|
|
U-55
|
|
TREATMENT OF PAIN
|
|
|
U-56
|
|
AID TO SMOKING CESSATION
|
|
|
U-57
|
|
OPHTHALMIC USE OF NORFLOXACIN
|
|
|
U-58
|
|
METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
|
|
|
U-59
|
|
METHOD OF TREATING HYPERCHOLESTEROLEMIA
|
|
|
U-60
|
|
NASAL ADMINISTRATION OF BUTORPHANOL
|
|
|
U-61
|
|
CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
|
|
|
U-62
|
|
CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
|
|
|
U-63
|
|
ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
|
|
|
U-64
|
|
TREATMENT OF VIRAL INFECTIONS
|
|
|
U-65
|
|
METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
|
|
|
U-66
|
|
TRIPHASIC REGIMEN
|
|
|
U-67
|
|
METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
|
|
|
U-68
|
|
TREATMENT OF ACTINIC KERATOSIS
|
|
|
U-69
|
|
TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
|
|
|
U-70
|
|
TREATMENT OF TRANSIENT INSOMNIA
|
|
|
U-71
|
|
METHOD OF TREATMENT OF HEART FAILURE
|
|
|
U-72
|
|
TREATMENT OF MIGRAINE
|
|
|
U-73
|
|
METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
|
|
|
U-74
|
|
METHOD OF PROVIDING HYPNOTIC EFFECT
|
|
|
U-75
|
|
RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
|
|
|
U-76
|
|
USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
|
|
|
U-77
|
|
TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
|
|
|
U-78
|
|
ULCERATIVE COLITIS
|
|
|
U-79
|
|
SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURNDUE TO GERD
|
|
|
U-80
|
|
METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
|
|
|
U-81
|
|
RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
|
|
|
U-82
|
|
TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
|
|
|
U-83
|
|
TREATMENT OF SEIZURES
|
|
|
U-84
|
|
A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
|
|
|
U-85
|
|
NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
|
|
|
U-86
|
|
METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
|
|
|
U-87
|
|
METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
|
|
|
U-88
|
|
TREATMENT OF MODERATE PLAQUE PSORIASIS
|
|
|
U-89
|
|
TREATMENT OR PROPHYLAXIS OF EMESIS
|
|
|
U-90
|
|
TREATMENT OF PYSCHOTIC DISORDERS
|
|
|
U-91
|
|
ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
|
|
|
U-92
|
|
TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY
|
|
|
U-93
|
|
USE AS AN ANTIHISTAMINE/DECONGESTANT
|
|
|
U-94
|
|
TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED
|
|
|
U-95
|
|
SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS
|
|
|
U-96
|
|
METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS
|
|
|
U-97
|
|
A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT
|
|
|
U-98
|
|
A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL
|
|
|
U-99
|
|
METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM
|
|
|
U-100
|
|
METHOD OF TREATING OCULAR INFLAMMATION
|
|
|
U-101
|
|
ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED
|
|
|
U-102
|
|
METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN
|
|
|
U-103
|
|
TREATMENT OF OCULAR HYPERTENSION
|
|
|
U-104
|
|
TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE
|
|
|
U-105
|
|
EMESIS
|
|
|
U-106
|
|
TREATMENT OF EPILEPSY
|
|
|
U-107
|
|
TREATMENT OF HYPERTENSION AND ANGINA PECTORIS
|
|
|
U-108
|
|
SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS
|
|
|
U-109
|
|
ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE
|
|
|
U-110
|
|
USE AS A RETRIEVABLE PERSSARY
|
|
|
U-111
|
|
DIABETES
|
|
|
U-112
|
|
CONTRACEPTION
|
|
|
U-113
|
|
METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE
|
|
|
U-114
|
|
USE FOR INHIBITING BONE RESORPTION
|
|
|
U-115
|
|
USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS
|
|
|
U-116
|
|
METHOD OF MYOCARDIAL IMAGING
|
|
|
U-117
|
|
TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES
|
|
|
U-118
|
|
METHOD OF LOWERING BLOOD SUGAR LEVEL
|
|
|
U-119
|
|
TREATMENT OF NASAL HYPERSECRETION
|
|
|
U-120
|
|
CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES
|
|
|
U-121
|
|
METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
|
|
|
U-122
|
|
A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
|
|
|
U-123
|
|
METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
|
|
|
U-124
|
|
TREATMENT OF ACNE
|
|
|
U-125
|
|
TREATMENT NEUROGENERATIVE DISEASES
|
|
|
U-126
|
|
TREATMENT OF GASTRITIS
|
|
|
U-127
|
|
METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
|
|
|
U-128
|
|
METHOD FOR TREATMENT OF TUMORS
|
|
|
U-129
|
|
METHOD TO DESTROY OR IMPAIR TARGET CELLS
|
|
|
U-130
|
|
MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
|
|
|
U-131
|
|
PHOTODAMAGED SKIN
|
|
|
U-132
|
|
INHIBITING HIV PROTEASE
|
|
|
U-133
|
|
MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
|
|
|
U-134
|
|
TREATMENT OF ACNE VULGARIS
|
|
|
U-135
|
|
ANTITUMOR AGENT
|
|
|
U-136
|
|
PROCESS FOR WASTE NITROGEN REMOVAL
|
|
|
U-137
|
|
METHOD OF TREATING BACTERIAL VAGINOSIS
|
|
|
U-138
|
|
TREATMENT OF ALLERGIC RHINITIS
|
|
|
U-139
|
|
TREATMENT OF ALLERGIC REACTIONS
|
|
|
U-140
|
|
USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
|
|
|
U-141
|
|
TREATMENT OF ULCERATIVE COLITIS
|
|
|
U-142
|
|
METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
|
|
|
U-143
|
|
BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
|
|
|
U-144
|
|
BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
|
|
|
U-145
|
|
BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
|
|
|
U-146
|
|
METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
|
|
|
U-147
|
|
DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2
|
|
|
U-148
|
|
DEVICE FOR COLLECTING A BREATH SAMPLE
|
|
|
U-149
|
|
METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
|
|
|
U-150
|
|
METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
|
|
|
U-151
|
|
RELIEF OF SYMPTOMS OF THE COMMON COLD
|
|
|
U-152
|
|
METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
|
|
|
U-153
|
|
TREATMENT OF INITIAL EPISODE GENITAL HERPES
|
|
|
U-154
|
|
METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
|
|
|
U-155
|
|
TREATMENT OF ERECTILE DYSFUNCTION
|
|
|
U-156
|
|
METHOD OF PROVIDING ANESTHESIA
|
|
|
U-157
|
|
TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
|
|
|
U-158
|
|
ANGINA
|
|
|
U-159
|
|
TREATMENT OF INTERSTITIAL CYSTITIS
|
|
|
U-160
|
|
TREATMENT OF BACTERIAL INFECTIOUS DISEASE
|
|
|
U-161
|
|
METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
|
|
|
U-162
|
|
METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
|
|
|
U-163
|
|
METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
|
|
|
U-164
|
|
METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
|
|
|
U-165
|
|
TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
|
|
|
U-166
|
|
TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
|
|
|
U-167
|
|
METHOD FOR TREATING HIV-1 INFECTION
|
|
|
U-168
|
|
METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
|
|
|
U-169
|
|
METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
|
|
|
U-170
|
|
METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
|
|
|
U-171
|
|
METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
|
|
|
U-172
|
|
TREATMENT OF GENITAL WARTS
|
|
|
U-173
|
|
ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
|
|
|
U-174
|
|
USE AS AN ANTIHISTAMINE AGENT
|
|
|
U-175
|
|
METHOD OF TREATING MALIGNANT TUMORS
|
|
|
U-176
|
|
METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
|
|
|
U-177
|
|
FUNGICIDE
|
|
|
U-178
|
|
FACILITATED ADHERENCE OF AGENTS TO SKIN
|
|
|
U-179
|
|
ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
|
|
|
U-180
|
|
TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
|
|
|
U-181
|
|
PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
|
|
|
U-182
|
|
USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
|
|
|
U-183
|
|
TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
|
|
|
U-184
|
|
TREATING ALLERGIC EYE DISEASES IN HUMANS
|
|
|
U-185
|
|
METHOD OF TREATING HYPERTENSION
|
|
|
U-186
|
|
METHOD FOR TREATING GI DISORDERS CAUSED BY H.RYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
|
|
|
U-187
|
|
THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
|
|
|
U-188
|
|
TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
|
|
|
U-189
|
|
ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
|
|
|
U-190
|
|
USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
|
|
|
U-191
|
|
METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
|
|
|
U-192
|
|
USE IN TREATING ALLERGIC REACTIONS
|
|
|
U-193
|
|
PSORIASIS
|
|
|
U-194
|
|
TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
|
|
|
U-195
|
|
METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOAC OR NITROGEN LABELED CARBON
|
|
|
U-196
|
|
TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
|
|
|
U-197
|
|
USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
|
|
|
U-198
|
|
TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
|
|
|
U-199
|
|
METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
|
|
|
U-200
|
|
METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
|
|
|
U-201
|
|
METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
|
|
|
U-202
|
|
METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS
|
|
|
U-203
|
|
TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
|
|
|
U-204
|
|
USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
|
|
|
U-205
|
|
METHOD FOR TREATING HEARTBURN
|
|
|
U-206
|
|
METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
|
|
|
U-207
|
|
USE AS NASAL SPRAY
|
|
|
U-208
|
|
VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
|
|
|
U-209
|
|
VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
|
|
|
U-210
|
|
METHOD OF TREATING CONGESTIVE HEART FAILURE
|
|
|
U-211
|
|
USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
|
|
|
U-212
|
|
METHOD OF TREATMENT OF PARKINSON'S DISEASE
|
|
|
U-213
|
|
METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
|
|
|
U-214
|
|
USE AS A BLOOD GLUCOSE-LOWERING AGENT
|
|
|
U-215
|
|
TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
|
|
|
U-216
|
|
TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
|
|
|
U-217
|
|
METHOD OF PRODUCING ANESTHESIA
|
|
|
U-218
|
|
METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
|
|
|
U-219
|
|
TREATMENT OF PARKINSON'S DISEASE
|
|
|
U-220
|
|
METHOD OF DIAGNOSIS
|
|
|
U-221
|
|
SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
|
|
|
U-222
|
|
METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
|
|
|
U-223
|
|
TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
|
|
|
U-224
|
|
CONTROLLING INTRAOCULAR PRESSURE
|
|
|
U-225
|
|
MEHTOD FOR DELIVERY
|
|
|
U-226
|
|
METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
|
|
|
U-227
|
|
NASAL ADMINISTRATION
|
|
|
U-228
|
|
ASTHMA
|
|
|
U-229
|
|
CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
|
|
|
U-230
|
|
PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
|
|
|
U-231
|
|
USE IN PARKINSON'S DISEASE
|
|
|
U-232
|
|
METHOD OF TREATING MIGRAINE
|
|
|
U-233
|
|
DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
|
|
|
U-234
|
|
METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
|
|
|
U-235
|
|
METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
|
|
|
U-236
|
|
TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
|
|
|
U-237
|
|
METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
|
|
|
U-238
|
|
IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED....
|
|
|
U-239
|
|
TREATING OR CONTROLLING OCULAR INFLAMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
|
|
|
U-240
|
|
TREATMENT OF ACUTE MIGRAINE ATTACKS
|
|
|
U-241
|
|
FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
|
|
|
U-242
|
|
USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
|
|
|
U-243
|
|
TOPICAL ADMINISTRATION
|
|
|
U-244
|
|
PLATELET AGGREGATION INHIBITORS
|
|
|
U-245
|
|
TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
|
|
|
U-246
|
|
PHOSPHATE BINDING
|
|
|
U-247
|
|
TREATMENT OF RHEUMATOID ARTHRITIS
|
|
|
U-248
|
|
TREATMENT OF HIV
|
|
|
U-249
|
|
METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
|
|
|
U-250
|
|
TREATMENT OF HEPATITIS B INFECTION
|
|
|
U-251
|
|
USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
|
|
|
U-252
|
|
METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
|
|
|
U-253
|
|
ORAL TRANSMUCOSAL USE
|
|
|
U-254
|
|
USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
|
|
|
U-255
|
|
IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
|
|
|
U-256
|
|
TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
|
|
|
U-257
|
|
TREATMENT OF HIV INFECTION
|
|
|
U-258
|
|
TREATMENT OF NEURODEGENERATIVE DISEASES
|
|
|
U-259
|
|
TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
|
|
|
U-260
|
|
REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
|
|
|
U-261
|
|
TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
|
|
|
U-262
|
|
TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
|
|
|
U-263
|
|
METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
|
|
|
U-264
|
|
METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
|
|
|
U-265
|
|
USE AS LAXATIVE
|
|
|
U-266
|
|
RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENNORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
|
|
|
U-267
|
|
PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
|
|
|
U-268
|
|
ACROMEGALY
|
|
|
U-269
|
|
EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
|
|
|
U-270
|
|
METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
|
|
|
U-271
|
|
METHOD OF TREATING TUMORS
|
|
|
U-272
|
|
METHOD OF TREATING CARCINOMA
|
|
|
U-273
|
|
CUTANEOUS T-CELL LYMPHOMA
|
|
|
U-274
|
|
ZANAMIVIR FOR INHALATION
|
|
|
U-275
|
|
METHOD OF USE OF THE DRUG SUBSTANCE
|
|
|
U-276
|
|
METHOD OF USE OF LEVOBUPIVACAINE
|
|
|
U-277
|
|
NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
|
|
|
U-278
|
|
METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
|
|
|
U-279
|
|
METHOD OF USE OF THE APPROVED PRODUCT
|
|
|
U-280
|
|
TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
|
|
|
U-281
|
|
ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
|
|
|
U-282
|
|
METHOD OF TREATING BACTERIAL INFECTIONS
|
|
|
U-283
|
|
METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
|
|
|
U-284
|
|
MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
|
|
|
U-285
|
|
DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
|
|
|
U-286
|
|
DEPRESSION
|
|
|
U-287
|
|
TREATMENT OR PREVENTION OF OSTEOPOROSIS
|
|
|
U-288
|
|
THERAPY OF INFLUENZA
|
|
|
U-289
|
|
TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
|
|
|
U-290
|
|
INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
|
|
|
U-291
|
|
INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
|
|
|
U-292
|
|
INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
|
|
|
U-293
|
|
INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
|
|
|
U-294
|
|
TREATMENT OF HYPERPIGMENTARY DISORDERS
|
|
|
U-295
|
|
TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
|
|
|
U-296
|
|
TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
|
|
|
U-297
|
|
PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
|
|
|
U-298
|
|
METHOD OF COMBATING BACTERIA IN A PATIENT
|
|
|
U-299
|
|
TREATMENT OF ADENOMATOUS POLYPS
|
|
|
U-300
|
|
INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
|
|
|
U-301
|
|
USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
|
|
|
U-302
|
|
TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
|
|
|
U-303
|
|
METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
|
|
|
U-304
|
|
A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
|
|
|
U-305
|
|
METHODS FOR USING THE DRUG PRODUCT
|
|
|
U-306
|
|
TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
|
|
|
U-307
|
|
CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
|
|
|
U-308
|
|
CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA
|
|
|
U-309
|
|
TREATING SJOEGREN SYNDROME
|
|
|
U-310
|
|
TREATMENT OF XEROSTOMIA
|
|
|
U-311
|
|
HORMONE REPLACEMENT
|
|
|
U-312
|
|
PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
|
|
|
U-313
|
|
TREATMENT OF CONGESTIVE HEART FAILURE
|
|
|
U-314
|
|
METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
|
|
|
U-315
|
|
METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
|
|
|
U-316
|
|
METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
|
|
|
U-317
|
|
METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
|
|
|
U-318
|
|
TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
|
|
|
U-319
|
|
TREATMENT OF MICROBIAL INFECTIONS
|
|
|
U-320
|
|
INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
|
|
|
U-321
|
|
REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
|
|
|
U-322
|
|
TREATMENT OF ALZHEIMER'S DEMENTIA
|
|
|
U-323
|
|
USE AS A BILE ACID SEQUESTRANT
|
|
|
U-324
|
|
METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
|
|
|
U-325
|
|
METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
|
|
|
U-326
|
|
METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
|
|
|
U-327
|
|
METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
|
|
|
U-328
|
|
METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
|
|
|
U-329
|
|
USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
|
|
U-330
|
|
TREATMENT OF NAUSEA AND VOMITING
|
|
|
U-331
|
|
METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
|
|
|
U-332
|
|
TREATMENT OR PREVENTION OF BRONCHOSPASM
|
|
|
U-333
|
|
METHOD OF TREATING OCULAR HYPERTENSION
|
|
|
U-334
|
|
TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
|
|
|
U-335
|
|
USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
|
|
|
U-336
|
|
DIAGNOSTIC RADIOIMAGING
|
|
|
U-337
|
|
USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
|
|
|
U-338
|
|
METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
|
|
|
U-339
|
|
PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
|
|
|
U-340
|
|
THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
|
|
|
U-341
|
|
METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
|
|
|
U-342
|
|
METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
|
|
|
U-343
|
|
REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
|
|
|
U-344
|
|
METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
|
|
|
U-345
|
|
RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION
|
|
|
U-346
|
|
METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS MTABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
|
|
|
U-347
|
|
METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
|
|
|
U-348
|
|
METHOD OF USE FOR INHIBITING HIV INFECTION
|
|
|
U-349
|
|
METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
|
|
|
U-350
|
|
PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
|
|
|
U-351
|
|
INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR
|
|
|
U-352
|
|
INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
|
|
|
U-353
|
|
PREVENTION AND TREATMENT OF OSTEOPOROSIS
|
|
|
U-354
|
|
METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
|
|
|
U-355
|
|
METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
|
|
|
U-356
|
|
DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
|
|
|
U-357
|
|
USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
|
|
|
U-358
|
|
DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
|
|
|
U-359
|
|
METHOD OF USE OF VISICOL
|
|
|
U-360
|
|
METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
|
|
|
U-361
|
|
MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
|
|
|
U-362
|
|
USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
|
|
|
U-363
|
|
METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
|
|
|
U-364
|
|
TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
|
|
|
U-365
|
|
METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
|
|
|
U-366
|
|
METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
|
|
|
U-367
|
|
TREATMENT OF CARDIOVASCULAR DISORDERS
|
|
|
U-368
|
|
HEARTBURN
|
|
|
U-369
|
|
METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
|
|
|
U-370
|
|
INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
|
|
|
U-371
|
|
APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
|
|
|
U-372
|
|
METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
|
|
|
U-373
|
|
GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
|
|
|
U-374
|
|
KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
|
|
|
U-375
|
|
METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
|
|
|
U-376
|
|
TREATMENT OF INFLUENZA
|
|
|
U-377
|
|
METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
|
|
|
U-378
|